Mensen, laten we HEB niet vergeten.. 9% erbij voorbeurs.
Stanford University Presents New Data On Immuno-Potential of Hemispherx's Ampligen(R)
May Enhance Bioactivity of Cancer Immunotherapies
* Press Release
* Source: Hemispherx Biopharma, Inc.
* On Friday October 2, 2009, 8:45 am EDT
PHILADELPHIA, Oct. 2, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), announced that Dr. Jonathan S. Berek, Professor and Chair, Obstetrics and Gynecology, Stanford University School of Medicine, presented new data on Ampligen(R) (Poly I : Poly C12U) at the Pacific Coast Oncology Gynecology Society Meeting, La Jolla, California, on October 1, 2009. The paper, entitled "Enhancing Dendritic Cell (DC) and Antibody Immunotherapy with Toll Receptor (TLR Agonists)," discusses the incorporation of a periodic "danger signal" into treatment regimens with a TLR3 agonist such as Poly I : Poly C12U and suggests such regimens may have broad potential application to boost the effects of immunotherapies of cancer.
Ampligen(R) (Poly I : Poly C12U), an experimental immunotherapeutic, is also being actively pursued as a pandemic influenza vaccine enhancer (Japanese National Institute of Infectious Diseases) and as potential monotherapy for chronic fatigue syndrome (CFS), in which the Company has a commercial application (NDA, new drug application) submitted and under review.